Volume 29, issue 7, July 2022

146 articles in this issue

1. 2022 SSO Presidential Address: What is a Surgical Oncologist? Evolution of Surgical Oncology and the Society of Surgical Oncology in an Era of Hyperspecialization

2. Spoiled for Choice: Do We Finally Have Clarity on Optimal Treatment Sequencing for Patients with Metastatic Melanoma Harboring an Actionable BRAF Mutation?

3. Minimally Invasive Mastectomy: It Is Coming Around the Mountain

4. Immediate Breast Reconstruction in Inflammatory Breast Cancer: Are We There Yet?

5. Comment on: "Determining Which Patients Require Preoperative Pelvic Radiotherapy Before Curative Intent Surgery and/or Ablation for Metastatic Rectal Cancer"

6. New Insights on the Importance of the Extent of Vascular Invasion in Encapsulated Angio-invasive Follicular Thyroid Carcinoma

7. Autofluorescence and Artificial Intelligence: The Future of Parathyroid Surgery?

8. Are Textbook Outcomes after Hepatectomy Only Possible at a Specific Weight?

9. Hepatocellular Carcinoma Recurrence Risk in the Context of Emerging Therapies

10. Good Bone Structure: A Call for Stronger Design and Methodology in Disparities Studies in Orthopedic Oncology

11. The Prevention of Venous Thromboembolism After Esophago-Gastric Surgery: A Never-Ending Story

12. Surgery for Lobar Bronchial Adenoid Cystic Carcinoma: It is R0, Not Location

13. Pathologic Complete Response Following Esophagectomy: Lymph Nodes Matter!

14. Two Decades of Pulmonary Metastasectomy for Leiomyosarcoma in Essen

15. Editorial Comment on: Functions and Clinical Significance of CACNA2D1 in Gastric Cancer: “Potential for Targeted Therapy against Gastric Cancer Stem Cells Using the Clinically Available Calcium Channel Blocker”

16. Image‐Guided Video-Assisted Thoracoscopic Surgery (iVATS) Versus Standard VATS Resection

17. A Phase III, Multicenter, Randomized Controlled Trial Investigating 1-cm Versus 2-cm Surgical Excision Margins for Stage II Primary Cutaneous Melanoma (MelMarT-II)

18. Association Between Underlying Comorbid Conditions and Stage of Presentation in Cutaneous Melanoma

19. Safety and Feasibility of Minimally Invasive (Laparoscopic/Robotic-Assisted) Nipple-Sparing Mastectomy Combined with Prosthesis Breast Reconstruction in Breast Cancer: A Single-Center Retrospective Study

20. ASO Visual Abstract: Safety and feasibility of Minimally Invasive (Laparoscopic/Robotic-Assisted) Nipple-Sparing Mastectomy Combined with Prosthesis Breast Reconstruction in Breast Cancer—A Single-Center Retrospective Study

21. The Role of Safety-Net Hospitals in Reducing Disparities in Breast Cancer Care

22. ASO Author Reflections: Reinforcing the Safety Net: Supporting Safety-Net Hospitals in Mitigating Breast Cancer Disparities

23. ASO Visual Abstract: The Role of Safety Net Hospitals in Reducing Disparities in Breast Cancer Care

24. Preoperative MRI and Its Impact on Surgical Outcomes in Patients with Triple Negative Breast Cancer Treated with Primary Surgery: Did New Margin Guidelines or Cavity Shave Margins Practice Diminish the Role of Preoperative MRI?

25. ASO Author Reflections: Does Use of Preoperative MRI Reduce Reexcision Rate in Patients with TNBC? Maybe, But It Is Complicated

26. ASO Visual Abstract: Preoperative MRI and Its Impact on Surgical Outcomes in Patients with Triple Negative Breast Cancer Treated with Primary Surgery: Did New Margin Guidelines or Cavity Shave Margins Practice Diminish the Role of Preoperative MRI?

27. Axillary Response to Neoadjuvant Therapy in Node-Positive, Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Breast Cancer Patients: Predictors and Oncologic Outcomes

28. ASO Visual Abstract: Axillary Response to Neoadjuvant Therapy in Node-Positive ER+/HER2- Breast Cancer Patients—Predictors and Oncologic Outcomes

29. Race and Site of Care Impact Treatment Delays in Older Women with Non-Metastatic Breast Cancer

30. ASO Visual Abstract: Race and Site of Care Impact Treatment Delays for Older Women with Non-Metastatic Breast Cancer

31. Impact of Screening Mammography on Treatment in Young Women Diagnosed with Breast Cancer

32. ASO Visual Abstract: Impact of Screening Mammography on Treatment in Young Women Diagnosed with Breast Cancer

33. Longitudinal Prospective Evaluation of Quality of Life After Axillary Lymph Node Dissection

34. ASO Author Reflections: Acute or Chronic? The Effect of Axillary Lymph Node Dissection on Arm Symptoms and Quality of Life Over Time

35. ASO Visual Abstract: Longitudinal Prospective Evaluation of Quality of Life After Axillary Lymph Node Dissection

36. Age-Independent Preoperative Chemosensitivity and 5-Year Outcome Determined by Combined 70- and 80-Gene Signature in a Prospective Trial in Early-Stage Breast Cancer

37. ASO Visual Abstract: Age-Independent Preoperative Chemosensitivity and 5-Year Outcome Determined by Combined 70- and 80-Gene Signature in a Prospective Trial in Early-Stage Breast Cancer

38. Facility-Level Variation of Low-Value Breast Cancer Treatments in Older Women with Early-Stage Breast Cancer: Analysis of a Statewide Claims Registry

39. ASO Visual Abstract: Facility-Level Variation of Low-Value Breast Cancer Treatments in Older Women with Early-Stage Breast Cancer: Analysis of a Statewide Claims Registry

40. Sexual Well-Being After Nipple-Sparing Mastectomy: Does Preservation of the Nipple Matter?

41. ASO Visual Abstract: Sexual Well-Being After Nipple-Sparing Mastectomy: Does Preservation of the Nipple Matter?

42. Variation in Deescalated Axillary Surgical Practices in Older Women with Early-Stage Breast Cancer

43. ASO Visual Abstract: Variation in Deescalated Axillary Surgical Practices in Older Women with Early-Stage Breast Cancer

44. Correction to: Clinical Outcomes Using Magnetic Seeds as a Non-wire, Non-radioactive Alternative for Localization of Non-palpable Breast Lesions

45. Determining Which Patients Require Preoperative Pelvic Radiotherapy Before Curative-Intent Surgery and/or Ablation for Metastatic Rectal Cancer

46. ASO Visual Abstract: Determining Which Patients Require Preoperative Pelvic Radiotherapy Before Curative Intent Surgery and/or Ablation for Metastatic Rectal Cancer

47. Oncologic Status of Obturator Lymph Node Metastases in Locally Advanced Low Rectal Cancer: A Japanese Multi-Institutional Study of 3487 Patients

48. ASO Author Reflections: Obturator Lymph Node Metastasis of Low Rectal Cancer

49. ASO Visual Abstract: Oncological Status of Obturator Lymph Node Metastases in Locally Advanced Low Rectal Cancer: A Japanese Multi-institutional Study of 3487 Patients

50. What is the Risk for Peritoneal Metastases and Survival Afterwards in T4 Colon Cancers?

51. ASO Author Reflections: Peritoneal Metastases After Curative-Intent Radical Resection of T4 Colon Cancers

52. ASO Visual Abstract: What is the Risk for Peritoneal Metastases and Survival Afterwards in T4 Colon Cancers?

53. Encapsulated Angioinvasive Follicular Thyroid Carcinoma: Prognostic Impact of the Extent of Vascular Invasion

54. ASO Author Reflections: Encapsulated Angio-Invasive Follicular Thyroid Carcinoma: Prognostic Impact of the Extent of Vascular Invasion

55. ASO Visual Abstract: Encapsulated Angioinvasive Follicular Thyroid Carcinoma: Prognostic Impact of the Extent of Vascular Invasion

56. A Visual Deep Learning Model to Localize Parathyroid-Specific Autofluorescence on Near-Infrared Imaging

57. ASO Visual Abstract: A Visual Deep Learning Model to Localize Parathyroid-Specific Autofluorescence on Near Infra-Red Imaging

58. Restratification of Patients with Intermediate-Risk Papillary Thyroid Carcinoma

59. ASO Visual Abstract: Restratification of Patients with Intermediate-Risk Papillary Thyroid Carcinoma

60. RET Fusion-Positive Papillary Thyroid Cancers are Associated with a More Aggressive Phenotype

61. ASO Visual Abstract: RET Fusion-Positive Papillary Thyroid Cancers are Associated with a More Aggressive Phenotype

62. Correction to: Volume Matters: Longitudinal Retrospective Cohort Study of Outcomes Following Consolidation and Standardization of Adrenal Surgery

63. Correction to: ASO Author Reflections: Volume Matters—Longitudinal Retrospective Cohort Study of Outcomes Following Consolidation and Standardization of Adrenal Surgery

64. Correction to: ASO Visual Abstract: Volume Matters—Longitudinal Retrospective Cohort Study of Outcomes Following Consolidation and Standardization of Adrenal Surgery

65. Association of Preoperative Body Mass Index with Surgical Textbook Outcomes Following Hepatectomy for Hepatocellular Carcinoma: A Multicenter Study of 1206 Patients

66. ASO Author Reflections: Prevalence and Factors Influencing Surgical Textbook Outcomes Among Patients Undergoing Liver Resection for Hepatocellular Carcinoma

67. ASO Visual Abstract: Association of Preoperative Body Mass Index with Surgical Textbook Outcomes following Hepatectomy for Hepatocellular Carcinoma: A Multicenter Study of 1206 Patients

68. Clinical Features of Recurrence After Hepatic Resection for Early-Stage Hepatocellular Carcinoma and Long-Term Survival Outcomes of Patients with Recurrence: A Multi-institutional Analysis

69. ASO Author Reflection: Clinical Characteristics and Long-Term Prognosis for Patients with Recurrence after Curative Resection for BCLC Stage 0/A Hepatocellular Carcinoma

70. ASO Visual Abstract: Clinical Features of Recurrence After Hepatic Resection for Early-Stage Hepatocellular Carcinoma and Long-Term Survival Outcomes of Patients with Recurrence: A Multi-institutional Analysis

71. Circulating Lipid- and Inflammation-Based Risk (CLIR) Score: A Promising New Model for Predicting Outcomes in Complete Colorectal Liver Metastases Resection

72. ASO Visual Abstract: Circulating Lipid- and Inflammation-Based Risk (CLIR) Score—A Promising New Model for Predicting Outcomes in Complete Colorectal Liver Metastases Resection

73. Tumor Necrosis Impacts Prognosis of Patients Undergoing Resection for T1 Intrahepatic Cholangiocarcinoma

74. ASO Visual Abstract: Tumor Necrosis Impacts the Prognosis of Patients Undergoing Resection for T1 Intrahepatic Cholangiocarcinoma

75. Systematic Review and Meta-Analysis of Prognostic Factors for Early Recurrence in Intrahepatic Cholangiocarcinoma After Curative-Intent Resection

76. ASO Visual Abstract: Systematic Review and Meta-analysis of Prognostic Factors for Early Recurrence in Intrahepatic Cholangiocarcinoma After Curative-Intent Resection

77. Laparoscopic Pancreatoduodenectomy with Resection of the Inferior Vena Cava and Reconstruction with a Peritoneal Patch

78. Laparoscopic Left Hemihepatectomy for Intrahepatic Cholangiocellular Carcinoma: An Adequate Lymphadenectomy is Also Possible in Artery Variation

79. Laparoscopic Left Hepatectomy with Resection of the Spiegel Lobe Using the Modified Caudate Lobe-First Approach

80. Robotic Central Bisectionectomy for Centrally Located Hepatic Malignant Tumor

81. Non-Private Health Insurance Predicts Advanced Stage at Presentation and Amputation in Lower Extremity High Grade Bone Sarcoma: A National Cancer Database Study

82. ASO Author Reflections: Insurance-Related Disparities in High Grade Bone Sarcoma of Lower Extremity

83. ASO Visual Abstract: Non-Private Health Insurance Predicts Advanced Stage at Presentation and Amputation in Lower Extremity High-Grade Bone Sarcoma: A National Cancer Database Study

84. Sarculator is a Good Model to Predict Survival in Resected Extremity and Trunk Sarcomas in US Patients

85. ASO Visual Abstract: Sarculator is a Good Model to Predict Survival in Resected Extremity and Trunk Sarcomas in US Patients

86. Correction: Morbidity and Outcomes After Distal Pancreatectomy for Primary Retroperitoneal Sarcoma: An Analysis by the Trans-Atlantic Australasian Retroperitoneal Sarcoma Working Group

87. Correction to: Analysis of Differentiation Changes and Outcomes at Time of First Recurrence of Retroperitoneal Liposarcoma by Transatlantic Australasian Retroperitoneal Sarcoma Working Group (TARPSWG)

88. Correction: ASO Visual Abstract: An Analysis of Differentiation Changes and Outcomes at the First Recurrence of Retroperitoneal Liposarcoma by the Transatlantic Australasian Retroperitoneal Sarcoma Working Group (TARPSWG)

89. Correction to: Postoperative Morbidity After Resection of Recurrent Retroperitoneal Sarcoma: A Report from the Transatlantic Australasian RPS Working Group (TARPSWG)

90. Incidence, Timing, and Outcomes of Venous Thromboembolism in Patients Undergoing Surgery for Esophagogastric Cancer: A Population-Based Cohort Study

91. ASO Author Reflections: Is it Time for a Tailored Approach to Venous Thromboembolism Prophylaxis in Patients with Esophagogastric Cancer?

92. ASO Visual Abstract: Incidence, Timing, and Outcomes of Venous Thromboembolism in Patients Undergoing Surgery for Esophagogastric Cancer: A Population-Based Cohort Study

93. Adenoid Cystic Carcinoma of Lobar Bronchial Origin: 20-Year Experience at a Single Institution

94. ASO Author Reflections: Surgery With or Without Additional Radiotherapy as a Therapeutic Strategy in ACC of Lobar Bronchial Origin

95. Long-Term Outcome After Histopathological Complete Response with and Without Nodal Metastases Following Multimodal Treatment of Esophageal Cancer

96. Prognostic Factors for Leiomyosarcoma with Isolated Metastases to the Lungs: Impact of Metastasectomy

97. Percentage of Newly Proposed High-Grade Patterns Is Associated with Prognosis of Pathological T1-2N0M0 Lung Adenocarcinoma

98. ASO Author Reflections: High Percentage of Newly Proposed High-Grade Patterns (Micropapillary, Solid, and Complex Glands) is Associated with Poor Prognosis of Early-Stage Invasive Lung Adenocarcinoma

99. ASO Visual Abstract: Percentage of Newly Proposed High-Grade Patterns Is Associated With Prognosis of Pathologic T1-2N0M0 Lung Adenocarcinoma

100. Development and Validation of the Optimal Circumferential Resection Margin in Pathological T3 Esophageal Cancer: A Multicenter, Retrospective Study

101. ASO Author Reflections: The Optimal Circumferential Resection Margin in Pathological T3 Esophageal Cancer

102. ASO Visual Abstract: Development and Validation of the Optimal Circumferential Resection Margin in Pathological T3 Esophageal Cancer: A Multicenter Retrospective Study

103. Impact of the Ratio of Visceral Fat Area (VFA) to Psoas Muscle Area (PMA) (V/P Ratio) on Survival for Surgically Resected Esophageal Cancer

104. ASO Author Reflections: Impact of the Ratio of the Visceral Fat Area (VFA) to Psoas Muscle Area (PMA) (V/P Ratio) on Survival for Patients with Surgically Resected Esophageal Cancer

105. ASO Visual Abstract: Impact of the Ratio of the Visceral Fat Area (VFA) to Psoas Muscle Area (PMA) (V/P Ratio) on Survival for Surgically Resected Esophageal Cancer

106. Fluorescence Imaging-Guided Identification of Thymic Masses Using Low-Dose Indocyanine Green

107. ASO Visual Abstract: Fluorescence Imaging-Guided Identification of Thymic Masses Using Low-Dose Indocyanine Green

108. Exposure to a Postoperative Hypercoagulable State Predicts Poor Prognosis After Transthoracic Esophagectomy in Patients with Esophageal Cancer

109. ASO Author Reflections: Can We Target a Postoperative Hypercoagulable State in the Acute Phase after Esophagectomy for Esophageal Cancer?

110. ASO Visual Abstract: Exposure to a Postoperative Hypercoagulable State Predicts Poor Prognosis After Transthoracic Esophagectomy in Patients with Esophageal Cancer

111. Body Mass Index-Adjusted Weight Loss Grading System and Cancer-Related Fatigue in Survivors 1 Year After Esophageal Cancer Surgery

112. ASO Visual Abstract: Body Mass Index-Adjusted Weight-Loss Grading System and Cancer-Related Fatigue in Survivors 1 Year After EsophagealCancer Surgery

113. Changes in Perioperative Platelet Lymphocyte Ratio Predict Survival in Oesophago-Gastric Adenocarcinoma

114. ASO Visual Abstract: Changes in Perioperative Platelet Lymphocyte Ratio Predict Survival in Esophagogastric Adenocarcinoma

115. Correction to: Fluorescence Imaging-Guided Identification of Thymic Masses Using Low-Dose Indocyanine Green

116. Functions and Clinical Significance of CACNA2D1 in Gastric Cancer

117. ASO Author Reflections: CACNA2D1 may have a Potential as a Biomarker for Cancer Growth and as a Therapeutic Target for Gastric Cancer

118. ASO Visual Abstract: Functions and Clinical Significance of CACNA2D1 in Gastric Cancer

119. Oxidative Stress Predicts Post-Surgery Complications in Gastrointestinal Cancer Patients

120. ASO Author Reflections: Oxidative Stress as a Predictor of Short-Term Outcome After Oncological Surgery for Gastrointestinal Cancer

121. ASO Visual Abstract: Oxidative Stress Predicts Post-surgery Complications in Gastrointestinal Cancer Patients

122. Predicting Genomic Alterations of Phosphatidylinositol-3 Kinase Signaling in Hepatocellular Carcinoma: A Radiogenomics Study Based on Next-Generation Sequencing and Contrast-Enhanced CT

123. ASO Author Reflections: Characterizing the Genomic Alterations in Hepatocellular Carcinoma by Contrast-Enhanced CT

124. ASO Visual Abstract: Predicting Genomic Alterations of Phosphatidylinositol-3 Kinase Signaling in Hepatocellular Carcinoma—A Radiogenomics Study Based on Next-Generation Sequencing and Contrast-Enhanced CT

125. LKB-1 Expression and High-Risk Histopathology are Independent Prognostic Factors for Patients with Oral Cavity Carcinoma

126. ASO Author Reflections: The Pursuit of Prognostic Factors to Fine-Tune Treatment Decisions in Patients with Oral Cavity Carcinoma

127. ASO Visual Abstract: The Intensity of LKB-1 Expression, High-Risk Histopathology and TNM Stages are Independent Prognostic Factors in Oral Cavity Carcinoma

128. Phase II Prospective, Open-Label Randomized Controlled Trial Comparing Standard of Care Chemotherapy With and Without Sequential Cytoreductive Interventions for Patients with Oligometastatic Foregut Adenocarcinoma and Undetectable Circulating Tumor Deoxyribose Nucleic Acid (ctDNA) Levels

129. ASO Author Reflections: The Utility of Circulating-Tumor DNA in Selecting Patients for Locoregional, Metastases-Directed Therapies in Oligometastatic Foregut Adenocarcinoma

130. Preoperative Muscle-Adipose Index: A New Prognostic Factor for Gastric Cancer

131. ASO Visual Abstract: Preoperative Muscle-Adipose Index—A New Prognostic Factor for Gastric Cancer

132. Is There a Benefit to Adjuvant Chemotherapy in Resected, Early Stage Pancreatic Ductal Adenocarcinoma?

133. ASO Author Reflections: The Survival Advantage Persists: Benefit of Adjuvant Chemotherapy in Resected, Stage IA Pancreatic Cancer

134. ASO Visual Abstract: Is There a Benefit to Adjuvant Chemotherapy in Resected, Early-Stage Pancreatic Ductal Adenocarcinoma?

135. Prediction of Recurrence Pattern of Pancreatic Cancer Post-Pancreatic Surgery Using Histology-Based Supervised Machine Learning Algorithms: A Single-Center Retrospective Study

136. ASO Author Reflections: Histology-Based Supervised Machine Learning Model Can Predict Recurrence Pattern of Pancreatic Cancer

137. ASO Visual Abstract: Prediction of Recurrence Pattern of Pancreatic Cancer Post-Pancreatic Surgery Using Histology-Based Supervised Machine Learning Algorithms–A Single-Center, Retrospective Study

138. Comment on: “Impact of Tumor Size on the Outcomes of Patients with Resectable Distal Pancreatic Cancer”

139. Response: Impact of Tumor Size on Outcomes for Patients with Resectable Distal Pancreatic Cancer

140. Resection Margins Assessment by Intraoperative Flow Cytometry in Pancreatic Cancer

141. Landmark Series: Importance of Pancreatic Resection Margins Response to Comments to the Editor—Resection Margins Assessment by Intraoperative Flow Cytometry in Pancreatic Cancer

142. The Role of Diffusion-Weighted Magnetic Resonance Imaging in Staging after Neoadjuvant Chemotherapy in Locally Advanced Pancreatic Adenocarcinoma

143. The Role of Diffusion-Weighted Magnetic Resonance Imaging in Staging After Neoadjuvant Chemotherapy in Locally Advanced Pancreatic Adenocarcinoma: Reply

144. Comment on “Surgery for Intraductal Papillary Mucinous Neoplasms of the Pancreas: Preoperative Factors Tipping the Scale of Decision-Making”

145. Response to the Comment on: “Surgery for Intraductal Papillary Mucinous Neoplasms of the Pancreas: Preoperative Factors Tipping the Scale of Decision-Making”